Quris Technologies Ltd., an Israeli startup in artificial intelligence for the pharmaceutical industry, announced today that it has raised an additional USD 9 million in seed funding, bringing its total amount raised to USD 37 million.
New investors GlenRock Capital, iAngels, Welltech Ventures, and Richter Group joined existing investors SoftBank Vision Fund 2 in leading the latest investment. The AI-powered “patient-on-a-chip” system created by the promising startup Quris offers an alternative to animal and human clinical trials for the development of new drugs. The company claims that by simulating clinical trials, its platform has the potential to revolutionize drug development.
Also Read: Achieving Sustainable Business Growth with Automation-Led ESG
It uses a combination of stem-cell-derived tissue and AI to accurately simulate the human body’s response to new drugs rather than testing them on humans or animals.
Check Out The New Enterprisetalk Podcast. For more such updates follow us on Google News Enterprisetalk News.
The platform covers e entire enterprise technology space- including emerging technologies like RPA, AI, cloud, automation, and the entire gamut of digital transformation tools, strategies and management decisions.
